Maximilian Ruschig

Technische Universität Braunschweig — Germany

Medicine · Health Sciences

7h-index404citations15works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(8), SARS-CoV-2 and COVID-19 Research(6), Toxin Mechanisms and Immunotoxins(3), Advanced Biosensing Techniques and Applications(3), COVID-19 Clinical Research Studies(2)

Publications15 total

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants
Frontiers in Immunology·2024· 4 citedOpen Access
Human antibodies neutralizing the alpha-latrotoxin of the European black widow
Frontiers in Immunology·2024· 2 citedOpen Access
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context
BioDrugs·2023· 7 citedOpen Access
Antibody Selection via Phage Display in Microtiter Plates
Methods in molecular biology·2023· 6 cited
Construction of Human Immune and Naive scFv Phage Display Libraries
Methods in molecular biology·2023· 1 cited
Antibody Selection in Solution Using Magnetic Beads
Methods in molecular biology·2023· 3 cited
Testing of Diamond Electrodes as Biosensor for Antibody-Based Detection of Immunoglobulin Protein with Electrochemical Impedance Spectroscopy
C – Journal of Carbon Research·2022· 1 citedOpen Access
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants
2022Open Access
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Frontiers in Cellular and Infection Microbiology·2021· 70 citedOpen Access
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Cell Reports·2021· 103 citedOpen Access
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Nature Communications·2021· 97 citedOpen Access
Baculovirus-free insect cell expression system for high yield antibody and antigen production
Scientific Reports·2020· 62 citedOpen Access
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
2020· 18 citedOpen Access
A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD Mutations
SSRN Electronic Journal·2020· 11 citedOpen Access
The Binary Toxin CDT of Clostridium difficile as a Tool for Intracellular Delivery of Bacterial Glucosyltransferase Domains
Toxins·2018· 19 citedOpen Access

Frequent Co-authors

Michael Hust(13), Federico Bertoglio(11), Maren Schubert(10), Nora Langreder(8), Stephan Steinke(8), Esther Veronika Wenzel(8), Giulio Russo(8), Viola Fühner(7), Philip Alexander Heine(7), Stefan Dübel(7), Doris Meier(6), Rico Ballmann(6), Kai-Thomas Schneider(6), Kristian Daniel Ralph Roth(6), Philipp Kühn(6), Marlies Becker(6), Luka Čičin‐Šain(6), Dorina Schäckermann(5), Kathrin Eschke(5), Yeonsu Kim(5)